Trial Profile
A randomized, double blind, placebo controled, multicenter phase study to evaluate the safety and efficacy of tyroserleutide for injection in hepatocellular carcinoma (HCC) patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Tyroserleutide (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shenzhen Kangzhe Pharmaceutical
- 10 Apr 2008 New trial record.